Cullinan Therapeutics has a robust T-cell engager pipeline, savvy management, and a strong cash position. Read more on what investors should know about the company.

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding ...

The European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML), cementing its lead over a rival drug from ...

The study, named IDEAL ( IaDademstat treatment for EssentiAL thrombocythemia ), is a multicenter, single-arm Phase II study to be conducted in Spain in adult patients with ET who are ...

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years after being rejected by the ...

CNS(Vafidemstat) Appointed renowned Rolando Gutierrez-Esteinou, M.D. as new CMO for CNSPreparing protocol resubmission to incorporate ...

General and administrative expenses were $1.7 and $5.6 million for the quarter and twelve months ended December 31, 2025, ...

Bhavana (Tina) Bhatnagar, DO, advocates for AI and diverse clinical trials to bridge equity gaps in precision oncology and value-based care.

EAE-induced neuroinflammation. Using immuohistochemistry, flow cytometry, and single-cell RNAseq of doublets to interrogate cell-cell interactions, the authors provide solid evidence that macrophages, ...